Literature DB >> 35207724

From Bench to Bedside in Precision Medicine: Diabetes Mellitus and Peri-Implantitis Clinical Indices with a Short-Term Follow-Up: A Systematic Review and Meta-Analysis.

Mario Dioguardi1, Stefania Cantore2,3, Salvatore Scacco2, Cristian Quarta1, Diego Sovereto1, Francesca Spirito1, Mario Alovisi4, Giuseppe Troiano1, Riccardo Aiuto5, Daniele Garcovich6, Vito Crincoli2, Luigi Laino7, Michele Covelli8, Annarita Malcangi9, Lorenzo Lo Muzio1, Andrea Ballini2,3,10,11, Michele Di Cosola1.   

Abstract

Background and objective: Diabetes mellitus (DM) refers to a group of metabolic disorders characterized by hyperglycemia resulting from impaired secretion or action of insulin. The high levels of glucose in the blood can negatively affect the healing processes through alterations in vascularization, bone remodeling, and with increased susceptibility to infections. Diabetes mellitus is therefore a risk factor not only for many systemic diseases, but also for localized problems such as peri-implantitis. The objective of this systematic review was to identify a clear relationship between peri-implant inflammation indices and glycemic levels, through the investigation of prospective studies that report data on a short-term follow-up period. Our hypothesis was that peri-implant inflammatory indices may already present themselves in a statistically significant way as altered in patients with DM compared to patients without DM. Materials and methods: This review was reported according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA).
Results: More than 992 records were identified in the PubMed, Scopus, and Cochrane Central Register of Controlled Trial electronic databases and only seven studies were included in the meta-analysis. The results of the meta-analysis report worse outcomes in patients with DM, even in the short period of six months, for peri-implatitis inflammation indices, such as Marginal bone loss (standardized (Std). mean difference (MD) 12\6 months 0.81 [0.45, 1.17]\1.82 [0.53, 3.10]), Bleeding on probing (Std. MD 12\6 months 2.84 [1.34, 4.34]\3.44 [1.41, 5.50]), Probing depth (Std. MD 12\6 months 1.14 [0.60, 1.68]\2.24 [0.66, 3.83]), and the plaque index (Std. MD 12 months 2.83 [0.09, 5.57]).
Conclusion: The literature linking glycaemic control to peri-implant disease is highly heterogeneous due to lack of consistency of the definition of peri-implantitis and its clinical indicators among studies. Therefore, interpretation of finding and relevance to clinical practice should be considered on individual bases. In the era of personalized medicine, the clinician should utilize individualized information from translational researches and analyze all risk factors to provide the patient with evidence-based treatment options.

Entities:  

Keywords:  bleeding on probing; clinical biochemistry; dental implants; diabetes mellitus; glycosylated hemoglobin HbA1c; marginal bone loss; peri-implantitis; plaque index; pocket depth; translational research

Year:  2022        PMID: 35207724      PMCID: PMC8878354          DOI: 10.3390/jpm12020235

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  33 in total

1.  Peri-implant evaluation in type 2 diabetes mellitus patients: a 3-year study.

Authors:  Gerardo Gómez-Moreno; Antonio Aguilar-Salvatierra; Jerónimo Rubio Roldán; Javier Guardia; Jordi Gargallo; José Luis Calvo-Guirado
Journal:  Clin Oral Implants Res       Date:  2014-03-31       Impact factor: 5.977

2.  Clinical and radiographic indices around narrow diameter implants placed in different glycemic-level patients.

Authors:  Abdulaziz Alsahhaf; Ibraheem F Alshiddi; Rana Saud Alshagroud; Khulud Abdulrahman Al-Aali; Fahim Vohra; Tariq Abduljabbar
Journal:  Clin Implant Dent Relat Res       Date:  2019-04-29       Impact factor: 3.932

3.  Risk factors for severe retinopathy in non-insulin dependent diabetes.

Authors:  T Dornan; C Peckar; J Steemson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-01

4.  A clinical prospective study on alveolar bone augmentation and dental implant success in patients with type 2 diabetes.

Authors:  Özgür Erdogan; Yurdanur Uçar; Ufuk Tatlı; Murat Sert; Mehmet Emre Benlidayı; Burcu Evlice
Journal:  Clin Oral Implants Res       Date:  2014-07-11       Impact factor: 5.977

5.  Marginal Bone Loss of Dental Implants in Patients with Type 2 Diabetes Mellitus with Poorly Controlled HbA1c Values: A Long-Term Retrospective Study.

Authors:  Adi Lorean; Hila Ziv-On; Vladimir Perlis; Zeev Ormianer
Journal:  Int J Oral Maxillofac Implants       Date:  2021 Mar-Apr       Impact factor: 2.804

Review 6.  Naturally Occurring SGLT2 Inhibitors: A Review.

Authors:  Habib Yaribeygi; Milad Ashrafizadeh; Thozhukat Sathyapalan; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Wound healing around endosseous implants in experimental diabetes.

Authors:  M L Nevins; N Y Karimbux; H P Weber; W V Giannobile; J P Fiorellini
Journal:  Int J Oral Maxillofac Implants       Date:  1998 Sep-Oct       Impact factor: 2.804

8.  Clinical, microbiological, and salivary biomarker profiles of dental implant patients with type 2 diabetes.

Authors:  Nikolaos Tatarakis; Janet S Kinney; Marita Inglehart; Thomas M Braun; Charles Shelburne; Niklaus P Lang; William V Giannobile; Tae-Ju Oh
Journal:  Clin Oral Implants Res       Date:  2013-02-27       Impact factor: 5.977

Review 9.  A systematic review and meta-analysis evaluating the survival, the failure, and the complication rates of veneered and monolithic all-ceramic implant-supported single crowns.

Authors:  Bjarni Elvar Pjetursson; Irena Sailer; Andrey Latyshev; Kerstin Rabel; Ralf-Joachim Kohal; Duygu Karasan
Journal:  Clin Oral Implants Res       Date:  2021-10       Impact factor: 5.021

View more
  1 in total

Review 1.  Photodynamic Therapy for Peri-Implant Diseases.

Authors:  Betul Rahman; Anirudh Balakrishna Acharya; Ruqaiyyah Siddiqui; Elise Verron; Zahi Badran
Journal:  Antibiotics (Basel)       Date:  2022-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.